Journal of Neuro-Oncology

, Volume 43, Issue 1, pp 79–86 | Cite as

Gossypol Treatment of Recurrent Adult Malignant Gliomas

  • Peter Bushunow
  • Marcus M. Reidenberg
  • John Wasenko
  • Jeffrey Winfield
  • Beverly Lorenzo
  • Sheila Lemke
  • Benjamin Himpler
  • Robert Corona
  • Thomas Coyle
Article

Abstract

Gossypol, a polyphenolic compound which depletes cellular energy by inhibition of several intracellular dehydrogenases, has been shown to have antiproliferative activity against human glial tumor cell lines in vitro and in nude mouse xenografts. Human trials of gossypol as a male contraceptive have demonstrated safety of long-term administration. We studied the activity of Gossypol 10 mg PO bid in 27 patients with pathologically confirmed glial tumors which had recurred after radiation therapy. Fifteen patients had glioblastoma, 11 patients anaplastic astrocytoma, 1 patient relapsed low grade glioma. Response was assessed every 8 weeks using CT/MRI scan and clinical criteria including decadron requirement. Treatment was continued until disease progression. Two patients had partial response (PR); 4 had stable disease for 8 weeks or more. One patient maintained a PR with improved KPS for 78 weeks. The other had a PR lasting 8 weeks. Toxicity was mild: 2 heavily pretreated patients had mild thrombocytopenia, 5 patients developed hypokalemia, 3 patients developed grade 2 hepatic toxicity and peripheral edema. Gossypol levels measured by HPLC did not correlate with response or toxicity in this study.

We conclude that gossypol is well tolerated and has a low, but measurable, response rate in a heavily pretreated, poor-prognosis group of patients with recurrent glioma. The presumed novel mechanism of action, lack of significant myelosuppression, and activity in patients with advance glioma support further study of gossypol as an antineoplastic agent.

malignant glioma gossypol lactate dehydrogenase isoenzymes chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fine H, Dear K, Loeffler J, Black P, Canellos G: Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993PubMedGoogle Scholar
  2. 2.
    Oude Weernink PA, Rijksen G, Staal GE: Phosphorylation of pyruvate kinase and glycolytic metabolism in three human glioma cell lines. Tumour Biol 12(6): 339–52, 1991PubMedGoogle Scholar
  3. 3.
    Stefanini M: Enzymes, Isozymes and enzyme variants in the diagnosis of cancer. Cancer 55: 1931–1936, 1985PubMedGoogle Scholar
  4. 4.
    Timperley W: Lactate dehydrogenase isozymes in tumors of the nervous system. Acta Neuropathol (Berl) 19: 20–24, 1974Google Scholar
  5. 5.
    Gerhardt W, Clausen J, Christensen E, Riishede J: Lactate dehydrogenase isoenzymes in the diagnosis of human benign and malignant brain tumors. J Nat Canc Inst 38(3): 343–57, 1967Google Scholar
  6. 6.
    Haglid K, Carlsson CA, Thulin CA: Lactate dehydrogenase isoenzymes and proteins in human gliomas. Neurochirurgia 13(1): 19–28, 1970PubMedGoogle Scholar
  7. 7.
    Egami H, Takeshita I, Fukui M, Kitamura K: Supernumerary lactate dehydrogenase isozymes in human gliomas. J Neurolog Sci 61(1): 1–12, 1983Google Scholar
  8. 8.
    Keniry MA, Hollander C, Benz CC: The effect of gossypol and 6-aminonicotinamide on tumor cell metabolism: a 31Pmagnetic resonance spectroscopic study. Biochem Biophys Res Com 164(2): 947–53, 1989PubMedGoogle Scholar
  9. 9.
    Qian SZ, Wang ZG: Gossypol: a potential antifertility agent for males. (Review). Ann Rev Pharm Toxicol 24: 329– 60, 1984PubMedGoogle Scholar
  10. 10.
    Benz C, Hollander C, Keniry M, James TL, Mitchell M: Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123. J Clin Invest 79(2): 517–23, 1987PubMedGoogle Scholar
  11. 11.
    Tso WW, Lee CS: Lactate dehydrogenase-X: an isozyme particularly sensitive to gossypol inhibition. Internat J Androl 5(2): 205–9, 1982Google Scholar
  12. 12.
    Teng CS: Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Contraception 52(6): 389–95, 1995PubMedGoogle Scholar
  13. 13.
    Ligueros M, Jeoung D, Tang B, Hochhauser D, Reidenberg M, Sonenberg M: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Brit J Canc 76(1): 21–8, 1997Google Scholar
  14. 14.
    Shidaifat F, Canatan H, Kulp S, Sugimoto Y, Zhang Y, Brueggemeier R, Somers W, WY. C, Wang H, Lin Y: Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res 17(2A): 1003–9, 1997PubMedGoogle Scholar
  15. 15.
    Seghal A: Molecular changes during the genesis of brain tumors. Sem Surg Onc 14(1): 3–12, 1998Google Scholar
  16. 16.
    Ford JM, Hait WN, Matlin SA, Benz CC: Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Letters 56(1): 85–94, 1991PubMedGoogle Scholar
  17. 17.
    Coyle T, Levante S, Shetler M, Winfield J: In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neuro-oncol 19(1): 25–35, 1994Google Scholar
  18. 18.
    Wu DF, Yu YW, Tang ZM, Wang MZ: Pharmacokinetics of (C=+)-, (C)-, and (+)-gossypol in humans and dogs. Clin Pharm Therapeut 39(6): 613–8, 1986Google Scholar
  19. 19.
    Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metabol 76(4): 1019–24, 1993Google Scholar
  20. 20.
    Han ML, Wang YF, Tang MY, Ge QS, Zhou LF, Zhu PD, Sun YT: Gossypol in the treatment of endometriosis and uterine myoma. Contribut Gyn Obstet 16: 268–70, 1987Google Scholar
  21. 21.
    Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30(6): 480–2, 1992PubMedGoogle Scholar
  22. 22.
    Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, Carbone P: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649–655, 1982PubMedGoogle Scholar
  23. 23.
    Coyle T, Baptista J, Winfield J, Clark K, Poiesz B, Kirshner J, Scalzo S, Newman-Palmer N, King R, Graziano S: Mechlorethamine, Vincristine, and Procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 8: 2014–2018, 1990PubMedGoogle Scholar
  24. 24.
    Stumpf WE, Sar M, Haider SG, Xue SP, Chen KQ: Sites of action of gossypol studied by autoradiography and enzyme histochemistry. Contraception 37(3): 257–67, 1988PubMedGoogle Scholar
  25. 25.
    Strom-Hansen T, Cornett C, Jaroszewski JW: Interaction of gossypol with amino acids and peptides as a model of enzyme inhibition. Internat J Pept Prot Res 34(4): 306–10, 1989Google Scholar
  26. 26.
    Liang XS, Rogers AJ, Webber CL, Ormsby TJ, Tiritan ME, Matlin SA, Benz CC: Developing gossypol derivatives with enhanced antitumor activity. Invest New Drugs 13(3): 181–6, 1995PubMedGoogle Scholar
  27. 27.
    Reidenberg MM, Gu Z-P, Lorenzo BJ et al.: Differences in serum potassium concentrations in normal men in different geographic locations. Clin Chem 39: 72–5, 1993PubMedGoogle Scholar
  28. 28.
    Gu Z-P, Segal S, Reidenberg MM: Serum potassium values in normal men in Shanghai compared with men from Shanghai living abroad. Clin Chem 40: 340, 1994PubMedGoogle Scholar
  29. 29.
    Zhou LF, Lei HP: (Effect of gossypol acetic acid on the uterus and ovary) (Chinese). Yao Hsueh Hsueh Pao – Act Pharm Sin 19(3): 220–3, 1984Google Scholar
  30. 30.
    Brada M, Sharpe G: Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? Eur J Canc 32A(13): 2193–4, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Peter Bushunow
    • 1
  • Marcus M. Reidenberg
    • 2
  • John Wasenko
    • 3
  • Jeffrey Winfield
    • 4
  • Beverly Lorenzo
    • 2
  • Sheila Lemke
    • 5
  • Benjamin Himpler
    • 5
  • Robert Corona
    • 6
  • Thomas Coyle
    • 4
    • 5
  1. 1.Department of Medicine and University of Rochester Cancer CenterUniversity of RochesterRochesterUSA
  2. 2.Departments of Pharmacology and MedicineCornell University Medical CollegeNYUSA
  3. 3.Department of RadiologySUNY Health Science CenterSyracuseUSA
  4. 4.Department of NeurosurgerySUNY Health Science CenterSyracuseUSA
  5. 5.Department of MedicineSUNY Health Science CenterSyracuseUSA
  6. 6.Department of PathologySUNY Health Science CenterSyracuseUSA

Personalised recommendations